A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer
Manuel M. Hidalgo, Elizabeth M. Bruckheimer, N.V. Rajeshkumar et al. · Molecular Cancer Therapeutics · 2011
Patients with many advanced solid cancers have very poor prognosis, and improvements in life expectancy are measured only in months. We have recently reported the remarkable clinical outcome of a patient with advanced, gemcitabine-resistant, pancreatic cancer who was later treated with DNA-damaging agents, on the basis of the observation of significant activity of this class of drugs against a personalized tumorgraft generated from the patient's surgically resected tumor. Here, we extend the approach to patients with other advanced cancers. Tumors resected from 14 patients with refractory advanced cancers were propagated in immunodeficient mice and treated with 63 drugs in 232 treatment regimens. An effective treatment regimen in the xenograft model was identified for 12 patients. One patient died before receiving treatment, and the remaining 11 patients received 17 prospectively guided treatments. Fifteen of these treatments resulted in durable partial remissions. In 2 subjects, no effective treatments were found. Overall, there was a remarkable correlation between drug activity in the model and clinical outcome, both in terms of resistance and sensitivity. The data support the use of the personalized tumorgraft model as a powerful investigational platform for therapeutic decision making and to efficiently guide cancer treatment in the clinic.
Cited by 406 works. doi:10.1158/1535-7163.mct-11-0233
Authors
- Manuel M. Hidalgo
- Elizabeth M. Bruckheimer
- N.V. Rajeshkumar
- Ignacio Garrido‐Laguna
- Elizabeth De Oliveira
- Belén Rubio‐Viqueira
- Steven J. Strawn
- Michael J. Wick
- David Sidransky
References
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
- Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
- Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002
- An In vivo Platform for Translational Drug Development in Pancreatic Cancer
- Cancer genomics: from discovery science to personalized medicine
- Clinical Cancer Advances 2008: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology
- KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient Selection
- Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer